Arecor presents data for Arestat™ formulation technology


21-03-2014

At the World Vaccine Congress in Washington DC next week, Arecor will present data showing how its Arestat™ formulation technology significantly improves temperature stability for major vaccine types.

Arecor Limited, a biotechnology company dedicated to the discovery and development of advanced liquid formulations of biologics, will present two posters at the 14 World Vaccine Congress in Washington DC on 24-26 March 2014. These will show data to demonstrate how their advanced Arestat™ formulation technology significantly improves stability across a variety of vaccine types, including adenovirus vectors and measles.

  • Stabilisation of live attenuated virus vaccines using Arestat™ advanced formulations.
  • Stabilisation of conjugate and recombinant vaccines using Arestat™ advanced formulations.

According to CEO Tom Saylor, Arestat™ technology represents a real breakthrough in the drive to overcome the challenges of delivering viable vaccines to hot countries: “Using Arestat™, we are able to produce reformulated liquid vaccines that reduce the need for both cold chain transportation and storage. In particular this is important for hot, remote and resource-limited regions. At the World Vaccine Congress we will show data from a range of case studies proving the versatility and robustness of our approach.”

Posters will be made available for viewing on the Arecor website http://www.arecor.com/

_______________________________________________

To read more information, click here.

Advancing today's therapies to enable healthier lives.

Arecor Therapeutics Plc